Open AccessInvestigation of drugs affecting hypertension in bevacizumab‐treated patients and examination of the impact on the therapeutic effect
Author(s) -
Yagi Kenta,
Mitstui Marin,
Zamami Yoshito,
Niimura Takahiro,
IzawaIshizawa Yuki,
Goda Mitsuhiro,
Chuma Masayuki,
Fukunaga Kimiko,
Shibata Takahiro,
Ishida Shunsuke,
Sakurada Takumi,
Okada Naoto,
Hamano Hirofumi,
Horinouchi Yuya,
Ikeda Yasumasa,
Yanagawa Hiroaki,
Ishizawa Keisuke
Publication year - 2021
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3587
Subject(s) - bevacizumab , medicine , adverse effect , oncology , colorectal cancer , retrospective cohort study , vascular endothelial growth factor , pharmacology , therapeutic effect , cancer , chemotherapy , vegf receptors
Background In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic efficacy. However, it is not clear whether drugs that control blood pressure influence bevacizumab's efficacy. In this study, we investigated drugs that may affect hypertension in bevacizumab‐treated patients and examined the impact on the therapeutic effect. Patients and methods We analyzed 3,724,555 reports from the third quarter of 2010 to the second quarter of 2015. All data were obtained from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) analysis. In this retrospective cohort study, we investigated a total of 58 patients diagnosed with colorectal cancer and treated for the first time with bevacizumab containing XELOX or mFOLFOX6 at The University of Tokushima Hospital between January 2010 and December 2015. The effect of the treatment was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.0. Thereafter, the effect was confirmed using Gene Expression Omnibus (GEO) and cultured cells. Results There are few reports in FAERS of hypertension in patients treated with omeprazole on bevacizumab. Based on the chart review, patients who used proton pump inhibitors (PPI) had a lower response to treatment than those who did not (response rate: 25% vs 50%). Furthermore, experiments on GEO and cell lines suggested that induction of vascular endothelial growth factor (VEGF) gene expression by PPIs is the cause of the reduced therapeutic effect. Conclusion PPIs prevent hypertension in bevacizumab‐treated patients but may reduce bevacizumab's anti‐tumoral effects by inducing VEGF expression.